Condition
HR+/HER2- Breast Cancer
ClinicalTrials.gov condition label
Clinical trials
26 shownOptimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26
RECRUITINGPre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast CancerNCT07702708 · 2026-06-01
RECRUITINGBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseNCT07492641 · 2026-05-22
RECRUITINGMarker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · 2026-04-29
RECRUITINGEfficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyNCT07581834 · 2026-01-21
RECRUITINGQL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast CancerNCT06967103 · 2025-09-08
RECRUITINGORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid TumorsNCT06998407 · 2025-08-20
RECRUITINGNeoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)NCT06874933 · 2025-05-04
RECRUITINGSerplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerNCT06860529 · 2025-04-15
RECRUITINGNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)NCT06977893 · 2025-03-24
RECRUITINGNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)NCT06611813 · 2024-06-11
RECRUITINGStudy of AVZO-021 in Patients With Advanced Solid TumorsNCT05867251 · 2023-08-30
RECRUITINGPredicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01
RECRUITINGKumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast CancerNCT07691333 · 2026-06-30
NOT_YET_RECRUITINGBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain MetastasesNCT07539753 · 2026-06-01
NOT_YET_RECRUITINGAbemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant TherapyNCT07599137 · 2026-05-30
NOT_YET_RECRUITINGCombined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast CancerNCT07254858 · 2025-12-01
NOT_YET_RECRUITINGHormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR RadiotherapyNCT07005882 · 2025-09-01
NOT_YET_RECRUITINGEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast CancerNCT07130643 · 2024-12-20
ACTIVE_NOT_RECRUITINGAdebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast CancerNCT06599216 · 2024-10-08
ACTIVE_NOT_RECRUITINGTo Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast CancerNCT06470633 · 2024-08-01
NOT_YET_RECRUITINGApatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast CancerNCT06447623 · 2024-06-11
ACTIVE_NOT_RECRUITINGTucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast CancerNCT05633914 · 2023-02-07
UNKNOWNAbemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.NCT05789771 · 2022-04-01
COMPLETEDA Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast CancerNCT04282031 · 2020-06-15
UNKNOWNA Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsNCT02983045 · 2016-12-19
COMPLETEDCommon interventions
AbemaciclibDRUG4LetrozoleDRUG4FulvestrantDRUG3PalbociclibDRUG3RibociclibDRUG3AVZO-021DRUG2ElacestrantDRUG2EpirubicinDRUG2Neoadjuvant Chemotherapy in Combination with ToripalimabDRUG2AdebrelimabDRUG1Adebrelimab+Dalpciclib+Standard Endocrine TherapyDRUG1Albumin PaclitaxelDRUG1ApatinibDRUG1Aromatase inhibitor and FulvestrantDRUG1AVZO-023DRUG1BGB-43395DRUG1BPI-1178DRUG1Brain RadiotherapyRADIATION1Capecitabine 500mgDRUG1CarboplatinDRUG1CDK4/6 InhibitorDRUG1CDK4/6 inhibitors+Endocrine TherapyDRUG1CyclophosphamideDRUG1DalpiciclibDRUG1Dalpiciclib 100mgDRUG1
Leading sponsors
First Affiliated Hospital of Zhejiang University3Fujian Cancer Hospital3Avenzo Therapeutics, Inc.2Henan Cancer Hospital2Azienda Ospedaliero-Universitaria Careggi1BeOne Medicines1Beta Pharma (Suzhou) Co., Ltd.1Blokhin's Russian Cancer Research Center1First Affiliated Hospital of Wenzhou Medical University1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1Fudan University1Harbin Medical University1Hunan Cancer Hospital1Nanfang Hospital, Southern Medical University1Nektar Therapeutics1
Trial status mix
RECRUITING13
NOT_YET_RECRUITING6
ACTIVE_NOT_RECRUITING3
COMPLETED2
UNKNOWN2
Phase mix
PHASE217
PHASE35
PHASE14
PHASE41
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.